⌘K

07:30:00·1393d

PRReleasevia Quantisnow

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

ByQuantisnow·Wall Street's wire, on your screen.

BWAY· BrainsWay Ltd.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Chief Scientist Roth Yiftach sold 7,000 units of Ordinary Shares, decreasing direct ownership by 0.65% to 1,072,305 units (SEC Form 4)
Amendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.
Director Mitrany Rayten Michal Ety sold 17,980 units of Ordinary Shares, decreasing direct ownership by 59% to 12,500 units (SEC Form 4)
Director Mitrany Rayten Michal Ety converted options into 27,500 units of Ordinary Shares and covered exercise/tax liability with 9,520 units of Ordinary Shares, increasing direct ownership by 144% to 30,480 units (SEC Form 4)
SEC Form 6-K filed by BrainsWay Ltd.